摘要
目的探讨注射用紫杉醇(白蛋白结合型)与顺铂联合应用对晚期非小细胞肺癌(NSCLC)的疗效。方法选择明确诊断为晚期NSCLC患者88例,并依据随机数字表法分为观察组及对照组,各44例。对照组给予吉西他滨联合顺铂化疗方案,观察组予以注射用紫杉醇(白蛋白结合型)与顺铂联合化疗。比较两组患者的临床疗效,治疗前后血清肿瘤标志物[细胞角蛋白19片段抗原21-1(CYFRA21-1)、糖类抗原125(CA125)、癌胚抗原(CEA)]水平,不良反应发生情况。结果治疗后,观察组客观缓解率(ORR)59.09%及疾病控制率(DCR)79.55%均显著优于对照组的36.36%、54.55%(P<0.05)。两组患者治疗前CYFRA21-1、CA125、CEA对比未见显著差异(P>0.05);治疗后,两组患者CYFRA21-1、CA125、CEA均较治疗前有所降低,且观察组CYFRA21-1、CA125、CEA下降幅度较对照组更明显(P<0.05)。观察组不良反应总发生率11.36%低于对照组的36.36%(P<0.05)。结论注射用紫杉醇(白蛋白结合型)同顺铂联合化疗对晚期NSCLC患者有确切疗效,能明显缓解患者临床症状,同时不良反应发生率低,值得临床广泛应用。
Objective To explore the efficacy of paclitaxel for injection(albumin-bound)combined with cisplatin in the treatment of advanced non-small-cell lung cancer(NSCLC).Methods A total of 88 patients with advanced NSCLC were selected and divided into an observation group and a control group according to random number table method,each with 44 cases.The control group was given gemcitabine and cisplatin chemotherapy regimen,and the observation group was given paclitaxel for injection(albumin-bound)and cisplatin chemotherapy regimen.Patients in both groups wree compared in terms of clinical efficacy,levels of serum tumor markers[cytokeratin fragment 19(CYFRA21-1),carbohydrate antigen 125(CA125),carcinoembryonic antigen(CEA)]and the occurrence of adverse reactions.Results After treatment,the objective response rate(ORR)of 59.09%and disease control rate(DCR)of 79.55%in the observation group were significantly better than 36.36%and 54.55%in the control group(P<0.05).There were no significant differences in CYFRA21-1,CA125 and CEA between the two groups before treatment(P>0.05).After treatment,CYFRA21-1,CA125 and CEA were decreased in both groups compared with those before treatment;the falling amplitude of CYFRA21-1,CA125 and CEA in the observation group were more significant than those in the control group(P<0.05).The total incidence of adverse reactions in the observation group was 11.36%,which was lower than 36.36%in the control group(P<0.05).Conclusion Paclitaxel for injection(albumin-bound)and cisplatin chemotherapy regimen has a definite effect on advanced NSCLC patients,can significantly alleviate clinical symptoms,and the incidence of adverse reactions is low,which is worthy of clinical wide application.
作者
马春明
MA Chun-ming(Department of Medical Oncology,Yingkou Hospital of Traditional Chinese Medicine,Yingkou 115000,China)
出处
《中国现代药物应用》
2024年第10期106-109,共4页
Chinese Journal of Modern Drug Application
